<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30405848</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1837-9664</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>9</Volume>                    <Issue>20</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Journal of Cancer</Title>                <ISOAbbreviation>J Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>MicroRNA-34 family in breast cancer: from research to therapeutic potential.</ArticleTitle>            <Pagination>                <MedlinePgn>3765-3775</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.7150/jca.25576</ELocationID>            <Abstract>                <AbstractText>MicroRNA (miRNA)-34 family (miR-34s), including miR-34a/b/c, is the most well studied non-coding RNAs that regulate gene expression post-transcriptionally. The miR-34s mediates the tumor suppressor function of p53 in the pathogenesis of breast cancer by targeting different oncogenes. This review focuses on the anti-oncogenic regulation of the miR-34s, emphasizing the major signaling pathways that are involved in the modulation of miR-34s in breast cancer. Moreover, it highlights how epigenetic modification by the p53/miR-34s axis regulates the proliferation, invasiveness, chemoresistance, and sternness of breast cancer. A better understanding of the molecular mechanisms of miR-34s will open new opportunities for the development of novel therapeutic strategies and define a new approach in identifying potential biomarkers for early diagnosis of breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Imani</LastName>                    <ForeName>Saber</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Ray-Chang</ForeName>                    <Initials>RC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry and Molecular Medicine, the George Washington University, Washington, DC 20052, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fu</LastName>                    <ForeName>Junjiang</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>J Cancer</MedlineTA>            <NlmUniqueID>101535920</NlmUniqueID>            <ISSNLinking>1837-9664</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Diagnosis</Keyword>            <Keyword MajorTopicYN="N">MicroRNA-34</Keyword>            <Keyword MajorTopicYN="N">Treatment.</Keyword>            <Keyword MajorTopicYN="N">Tumor suppressor miRNA</Keyword>        </KeywordList>        <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30405848</ArticleId>            <ArticleId IdType="doi">10.7150/jca.25576</ArticleId>            <ArticleId IdType="pii">jcav09p3765</ArticleId>            <ArticleId IdType="pmc">PMC6216011</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>